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Aims: To determine whether protein–creatinine ratio (PCR) and albumin–creatinine ratio (ACR) are compa-
rable to 24 h urine protein in terms of agreement and repeatability, and therefore whether they are suitable
for monitoring and comparing reduction in proteinuria in clinical trials of endothelin receptor antagonists.
Main methods: Using data from a recent study of sitaxentan in 27 patients with proteinuric chronic kidney
disease, the assays were compared with reference to their agreement, repeatability, the number of measure-
ments required to obtain accurate results and correlation with reduction in proteinuria at baseline.
Key ﬁndings: The median coefﬁcient of variation was lower for PCR than 24 h urine protein (25 vs. 28%) but
the range was higher (70 vs. 47%). When converted into the same units, mean difference between 24 h urine
protein and both PCR (0.03 g/day), and ACR (0.10 g/day), was small. However, scatter increased with mean
level of proteinuria, such that agreement fell substantially above 1.5 g/day. According to 2-factor within-
subjects ANOVA, the assay used was not a signiﬁcant source of variation (PCR p=0.63, ACR p=0.38).
With 3 measurements at each time point, baseline proteinuria correlated equally well with change in pro-
teinuria, and percentage change was detected accurately by all 3 methods.
Signiﬁcance: PCR and ACRmay well be suitable replacements for 24 h urine protein in the clinical trial context
due to their similar accuracy and repeatability, greater convenience and lower cost. However, a randomised
control trial comparing all 3 assays in a larger and more diverse population is necessary before 24 h urine
protein can be replaced.© 2012 Elsevier Inc. All rights reserved.Introduction
Within the last two decades it has been established that protein-
uria is not only a marker of the severity of chronic kidney disease
(CKD), but also contributes directly to disease progression. Protein
overload of proximal tubular cells promotes an inﬂammatory re-
sponse that ultimately results in interstitial ﬁbrosis (Abbate et al.,
2006). It has since been demonstrated in both animal models and
clinical trials that lowering urine protein retards the progression of
CKD and can, in some cases, lead to disease remission (Remuzzi et
al., 2006; The GISEN group (1997). Consequently, interventions
which reduce the extent of urinary protein excretion are a key target
for the treatment of CKD, which has a prevalence of around 12% in the
European population (de Zeeuw et al., 2005).arch Institute, Room E3.22, 47
dom. Tel.: +44 131 242 9215;
rights reserved.In order to compare the antiproteinuric effects of various drugs, an
accurate and repeatable assay for urine protein is required. The cur-
rent gold standard for assessment of proteinuria is 24 h urine protein
excretion, and alternative methods must therefore be evaluated by
comparison with this assay. Whilst 24 h urine collections overcome
the problem of circadian rhythmicity in urine protein excretion
(Koopman et al., 1989), inconvenience and patient forgetfulness
often lead to incomplete collections and consequently, inaccurate as-
sessment of proteinuria (Price et al., 2005). Furthermore, handling
and analysis of 24 h urine samples is more costly and open to error
than alternative approaches. By contrast, protein–creatinine ratio
(PCR) and albumin–creatinine ratio (ACR) can be calculated from
spot urine samples,with urine protein or albumin concentration divided
by creatinine concentration to correct for variation in urine volume. Spot
samples are both cheaper andmore convenient than24 h samples, and a
number of studies have demonstrated the ability of both PCR andACR to
rule out signiﬁcant proteinuria (Guy et al., 2009) and predict renal out-
comes and mortality (Methven et al., 2010; Heerspink et al., 2010) in
patients with CKD. As a result, they have largely replaced 24 h urine
protein measurements in clinical screening for proteinuria. ACR is
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population (National Collaborating Centre for Chronic Conditions,
2008; Scottish Intercollegiate Guidelines Network, 2008; National
Kidney Foundation, 2002), whereas some groups favour PCR in patients
without diabetes (Scottish Intercollegiate Guidelines Network, 2008).
However, the characteristics whichmake PCR and ACR suitable alterna-
tives for screening purposes differ from those required to monitor
change in proteinuria with a drug candidate. Screening assays are pri-
marily used to stratify a target population into broad groups, whereas
in drug trials the absolute level of proteinuria is required, demanding
a higher degree of accuracy from the assay. Large drug trials such as
AASK have used PCR as a surrogate for 24 h urine protein, but have
not compared the two assays with each other (Lea et al., 2005).
The endothelin system represents an ideal target for antiproteinu-
ric interventions. It is now clear that upregulation of this system is not
merely a consequence of increased urine protein excretion, but that it
also plays a part in exacerbating the degree of proteinuria, primarily
through activation of ETA receptors (Barton, 2008; Neuhofer and
Pittrow, 2009). Sitaxentan is a selective ETA antagonist, the effects
of which were examined in a recent study in subjects with CKD
(Dhaun et al., 2011). At the end of the 6-week treatment period, pro-
teinuria had fallen by an average of 30%. Using data from this study,
we tested the hypothesis that PCR or ACR are suitable replacements
for 24 h urine protein in the measurement of proteinuria in clinical
trials of antiproteinuric drugs. Their suitability was assessed in
terms of agreement, repeatability, the requirement for multiple mea-
surements to obtain accurate readings and correlation with change in
proteinuria at baseline.
Materials and methods
Study subjects and protocol
The clinical study was carried out in 27 subjects with stable, stage
1 to 4 non-diabetic CKD and overt proteinuria (>300 mg/day). This
double-blind study involved three consecutive 6-week phases in
which subjects were randomly assigned to placebo, nifedipine LA
30 mg and sitaxentan 100 mg. All 27 subjects participated in all 3
phases, each of which was separated by a 2-week washout period.
Measurements were made on 3 consecutive days prior to the start
of treatment, at the end of week 3, and at the end of week 6 in each
phase. In accordance with written instructions, urine was collected
by the subject for 24 hours on each of these days, from which urine
protein was measured. PCR was determined from an aliquot of the
ﬁrst and second 24 h collections at each time point, whilst on the
third day a true spot urine was taken at the end of the 24 h period.
ACR was measured retrospectively from frozen urine samples, al-
though only one was available for each time point. Urine protein
was measured using a colorimetric method with pyrogallol red and
urine albumin with an immunoturbidimetric assay.
Statistical analysis
Data were analysed using SPSS 17 (SPSS Inc.). A statistical signiﬁ-
cance level of 0.05 was used for all hypothesis testing. Spearman's rho
was used to measure the strength of the correlation between mean
24 h urine protein and PCR from an aliquot (days 1 and 2) or a true
spot urine (day 3). It was also used to assess correlation between
baseline proteinuria and change in proteinuria with each of the as-
says. To enable direct comparison with 24 h urine protein (g/day),
PCR and ACR data (mg/mmol) had to be expressed in the same
units. In the absence of a standardised conversion factor between
the assays, the equation of the regression line derived from a scatter
plot of 24 h urine protein against aliquoted PCR and ACR was applied
to the raw data (24 h urine protein=73.3*PCR+7.7 and 59.2*ACR –
15.4). Bland-Altman plots were then constructed using thesetransformed data, for a visual and quantitative comparison of agree-
ment. The limits of agreement and their 95% conﬁdence intervals
were also calculated, and assessed for clinical signiﬁcance. The coefﬁ-
cient of repeatability and coefﬁcient of variation were used to com-
pare the repeatability of 24 h urine protein and PCR. It was not
possible to include ACR in this analysis as only one measurement
was available for each time point. Two-factor within-subjects
ANOVA was performed to assess the signiﬁcance of time and the
assay used as sources of variance in the measurement of proteinuria.
This analysis was also used to test the signiﬁcance of multiple mea-
surements on the percentage reduction in proteinuria reported by
each of the assays.
Results
PCR: aliquot vs. true spot urine
The correlation between PCR and mean 24 h urine protein at base-
line was calculated separately for measurements made on days 1, 2
and 3 (PCR 1, 2 and 3). Correlation of PCR 3 with mean 24 h urine pro-
tein (spot urine, rho=0.96) was similar to that of PCR 1 and PCR 2
(aliquots of 24 h urine collection, rho=0.94 and rho=0.97 respec-
tively). Likewise, Spearman's rho was comparable for all three PCR
readings when week 3 and week 6 were included in the analysis
(rho=0.96, rho=0.97 and rho=0.96 respectively). In all cases the
correlation was highly signiﬁcant (pb0.0001). In addition, the median
coefﬁcient of variation (CV) was consistent between PCRs measured
on days 1, 2 and 3 at all 3 time points in the placebo phase (23.4%,
24.4% and 24.1% respectively).
Agreement
Agreement of PCR and ACR with 24 h urine protein was assessed
using the Bland-Altman method (day 3, baseline, placebo phase)
[Fig. 1a and b]. As anticipated with data transformed in the manner
described above, the mean difference was small in both cases
(PCR=0.03 g/day, ACR=0.10 g/day). However, with the inclusion
of their 95% conﬁdence intervals, the limits of agreement span a
very large range (PCR=−2.29 to 2.25 g/day, ACR=−1.58 to
1.78 g/day). Fig. 1 also suggests that scatter increases with rising
levels of proteinuria. The data remain relatively clustered below
1.5 g/day with both PCR [Fig. 1a] and ACR [Fig. 1b], but above this
value greater variation is apparent. Adjustment was not made for
this possible downward trend in agreement both because it was not
consistent across the full range of mean concentrations and because
there were insufﬁcient data to conﬁrm that the trend was genuine.
Repeatability
The mean coefﬁcient of repeatability (CR) for day 3 readings at
baseline was lower with ACR (2.02 g/day) than with PCR (2.38 g/day)
and 24 h urine protein (2.46 g/day). The median CV for all 9 placebo
readings was higher with 24 h urine protein than PCR (28% vs. 25%)
[Fig. 2a]. Similarly, the median CV was higher for 24 h urine protein at
all 3 time points in all 3 phases (mean=17% vs. 14%), with the sole ex-
ception of week 3 in the nifedipine phase. However, the range of PCR
datawas greater than that of 24 h urine protein at baseline in the place-
bo phase (span=70% vs. 47%). Box plots constructed from the data
gathered atweek6 support this observation in the nifedipine and sitaxen-
tan phases, although not in the placebo phase [Fig. 2b].
Neither the assay used (p=0.80), nor time (p=0.61), nor the
interaction between assay and time (p=0.63), were identiﬁed as sig-
niﬁcant sources of variation in the data by 2-factor within-subjects
ANOVA (n=27). These ﬁndings were reproduced with the trans-
formed ACR data (p=0.54, p=0.63 and p=0.38 respectively).
Fig. 1. Bland-Altman plot of (A) 24 h urine protein and transformed protein–creatinine
ratio (tPCR) values and (B) 24 h urine protein and transformed albumin–creatinine
ratio (tACR) values. Dotted lines show the 95% CIs for the limits of agreement.
Fig. 2. Box plot of the coefﬁcient of variation of (A) 24 h urine protein and protein–
creatinine ratio (PCR) on all three days at baseline, week 3 and week 6 in the placebo
phase [n=81] and (B) 24 h urine protein and PCR on all three days at week 6 of each
phase. n=27. ○ = more than 1.5 box lengths above the box, Δ = more than 3 box
lengths above the box.
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Taking an average of three 24 h urine protein or PCR measure-
ments tended to demonstrate a slightly larger reduction in protein-
uria than with only 1 or 2 measurements, but this trend was not
signiﬁcant for either assay. According to Two-factor within-subjects
ANOVA, neither the number of repeat measurements nor number of
repeat measurements–time interaction were signiﬁcant for 24 h
urine protein (p=0.58, p=0.48) or PCR (p=0.85, p=0.53).Correlation with change in proteinuria at baseline
The correlation of mean baseline proteinuria with mean change in
proteinuria in the sitaxentan phase was calculated for 24 h urine
protein and PCR. Spearman's rho was similar (rho=−0.80 and
rho=−0.78 respectively) [Fig. 3a and b] and highly signiﬁcant in
both cases (pb0.0001).
Using day 3 measurements only, PCR demonstrated a stronger cor-
relation between baseline and change in proteinuria (rho=−0.76)
than both ACR and 24 h urine protein (rho=−0.57, rho=−0.55)
[Fig. 3c, d and e]. Spearman's rho was signiﬁcant in all cases
(pb0.0001, p=0.003 and p=0.007 respectively).Discussion
We have demonstrated that PCR is comparable to 24 h urine pro-
tein in terms of repeatability, the number of measurements required
to obtain accurate results and its correlation with reduction in pro-
teinuria at baseline. ACR is also comparable to 24 h urine protein
with regards to repeatability and association with change in protein-
uria. These ﬁndings indicate that both PCR and ACR may be suitable
alternatives to 24 h urine protein for monitoring change in protein-
uria in clinical trials of antiproteinuric drugs, such as endothelin re-
ceptor antagonists.
One of the main problems associated with 24 h urine protein is
poor compliance, which often results in inaccurate collections. In
this study, 24 h urine creatinine excretion did not differ signiﬁcantly
from placebo at week 3 or week 6 in either the nifedipine or sitaxen-
tan phases, indicating that collection of 24 h urine samples was con-
sistent throughout. However, the consistency of these collections
might not have been as robust were it not for the comprehensive
written and verbal instructions given over the course of the study.
Conversely, a key characteristic favouring PCR is the ability to mea-
sure proteinuria from a single spot sample. However, in this study
the ﬁrst and second PCR reading at each time point was calculated
from an aliquot of the 24 h collection, which could potentially mask
the circadian rhythmicity of proteinuria that affects true spot sam-
ples. As convenience is the distinguishing characteristic of the PCR
assay, it was important to establish whether the ﬁrst two PCR mea-
surements produced values that were comparable to the third PCR
from a true spot urine. Indeed, measurements with all three PCRs
Fig. 3. Correlation between baseline proteinuria and change in proteinuria with (A) 24 h urine protein, (B) protein–creatinine ratio (PCR), (C) 24 h urine protein – day 3 only,
(D) PCR – day 3 only, and (E) albumin–creatinine ratio (ACR) – day 3 only. Spearman's rho is shown in the bottom left corner of each plot.
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tein, and in all cases this correlation was highly signiﬁcant. Further-
more, the median CV of PCR measurements was consistent on all
three days, suggesting that repeatability with the aliquots and true
spot urine samples was comparable.
Correlation, however, is not an indicator of agreement but rather a
measure of the strength of association between two quantitative
variables. Therefore, the Bland-Altman method was used to assess
the degree of agreement between the assays. From Fig. 1 it appears
that as mean proteinuria increases, agreement falls, as demonstratedby an increase in scatter above 1.5 g/day. The reason for this apparent
decrease in agreement is not certain, but may be due to a decline in
the accuracy of the assays above their linear range, where manual dilu-
tions are performed. Indeed, urine samples with very high protein (in-
cluding albumin) concentrations can be erroneously reported as low
or normal with certain immunoassay techniques (Lamb et al., 2009).
This is known as the prozone phenomenon and results from the pres-
ence of very high concentrations of antigen. This phenomenon could
have affected the immunoturbidimetric assay for urine albumin, but is
not relevant with the colorimetric urine protein assay. The second
737J.D. Towler et al. / Life Sciences 91 (2012) 733–738observation to be made from Fig. 1 is the wide span of the limits of
agreement in both comparisons. Differences within this range are
clearly signiﬁcant in the clinical context, indicating that 24 h urine
protein and transformed PCR or ACR values cannot be considered
interchangeable.
Median variability of PCR was lower than 24 h urine protein, both
before and during active treatment, but the overall range of PCR readings
was greater. The difference in inter-quartile range between assays was
small, indicating that the increase in overall range was the result of
one or two subjects with variation that was high, but not sufﬁcient for
them to be considered outliers. With a sample size of only 27, it is not
possible to state whether measurements in these subjects were anoma-
lous or if signiﬁcant variation is a genuine issue in a small subset of the
population. The mean coefﬁcient of repeatability was similar with 24 h
urine protein and PCR, and lowest with ACR. When both PCR and ACR
were compared with 24 h urine protein, neither assay, nor time, nor
the assay x time interaction, were signiﬁcant, indicating that variance
is comparable in all three methods. Therefore, taking into account the
lower median CV, comparable mean CR and non-signiﬁcant ANOVA
ﬁndings, repeatability with PCR appears to be at least equivalent to
24 h urine protein. Likewise, considering the lower CR and non-
signiﬁcant ANOVA ﬁndings, repeatability with ACR seems to be compa-
rable to that of 24 h urine protein.
In addition to cumbersome 24 h collections, the other main incon-
venience related to monitoring proteinuria is the use of repeat mea-
surements. In the clinical study, three 24 h collections were taken at
baseline, week 3 and week 6; a total of 27 collections over three
phases. Without great care, poor compliance is likely to be com-
pounded by this number of repeats. Therefore, we investigated
what impact taking only one or two measurements would have had
on the outcome of the study. Using an average of three measurements
at each time point tended to demonstrate a greater reduction in pro-
teinuria than would have been apparent with fewer measurements.
This observation was made with both 24 h urine protein and PCR,
suggesting that it was not purely incidental. However, according to
Two-factor within-subjects ANOVA, neither number of repeats, nor
the number of repeat measurements–time interaction were statisti-
cally signiﬁcant, indicating a lack of evidence that number of repeat
measurements has an effect on percentage change in proteinuria or
that the extent of such an effect can vary signiﬁcantly according to
time. This is reﬂected in the wide conﬁdence intervals of percentage
change in proteinuria, especially with a single reading at each time
point (±15% for 24 h urine protein, ±17% for PCR, ±13% for ACR).
Therefore, in the majority of cases taking one or two measurements
at each time point would have been sufﬁcient to obtain a reasonable
picture of average reduction in proteinuria at the group level. However,
the high CV for both assaysmeans that this could lead to grossly inaccu-
rate assessment of proteinuria on an individual basis. As such, it is advis-
able to carry out three repeats to average out anomalous data and
ensure reliable results in all subjects. This is true for both 24 h urine pro-
tein and PCR.
A meta-analysis of 11 studies using ACE inhibitors in non-diabetic
renal disease found that patients with the highest urine protein ex-
cretion at baseline have the greatest reduction in proteinuria with
treatment (Jafar et al., 2001). We compared the correlation of mean
baseline proteinuria with mean change in proteinuria for each assay
to see if this observation was upheld with an ETA antagonist. All
three assays demonstrated a strong correlation with change in pro-
teinuria at baseline. The strength of this association increased when
three 24 h urine protein measurements were considered, and was
consistently high with both one and three PCR measurements. There-
fore, all three assays support the conclusion that patients with high
baseline urine protein excretion experience the greatest reduction
in proteinuria with sitaxentan.
This clinical study had a number of limitations which should be
addressed before 24 h urine protein can be legitimately replaced byspot tests. The ﬁrst is the size of the study sample. There were 27 sub-
jects involved in the clinical trial, which provided the power neces-
sary to meet the primary endpoint and demonstrate a signiﬁcant
reduction in proteinuria. However, it is possible that a larger sample
size may have unmasked signiﬁcance in a number of the statistical
tests carried out in this study. Therefore, it is not appropriate to
make generalisations from this study about the characteristics of
each assay in the general population, due to the small sample size.
The second limitation is the exclusion criteria. Notably, this study
was in patients with non-diabetic CKD and therefore the results pre-
sented here may not apply to those with diabetes mellitus or other
signiﬁcant comorbidities such as heart or lung disease and peripheral
vascular disease. The third limitation relates to the time at which the
spot urine (PCR 3) was taken. Koopman et al. (Koopman et al., 1989)
found that the greatest correlation with 24 h urine protein is ob-
served with a PCR from an early morning specimen. Patients in this
study voided the day 3 spot sample in the morning, which may
have strengthened the correlation between PCR 3 and mean 24 h
urine protein. The fourth limitation pertains to the storage of spare
samples from which the ACR was determined. Freezing samples at
−20 °C has been shown to yield erroneously low urinary albumin
concentrations, the magnitude of which increases with the duration
of storage (Brinkman et al., 2005). However, storage at −80 °C and
assessment by immunonephelometry has been shown to prevent
loss of albumin at 12 months (Brinkman et al., 2007). Spare samples
used in this study were stored at −80 °C but detection was with an
immunoturbidimetric method. Also, samples were stored for
4 years, the impact of which has not been investigated at this low
temperature. Whilst further research into the effects of frozen storage
with different detection methods may be of some use in interpreting
these results, minimising the duration of storage is likely to yield a
more accurate comparison of multiple assays.Conclusion
Since repeat measurements are advisable regardless of the assay,
and since spot urines are far more convenient and less open to error
than 24 h urine collections, it is only necessary to demonstrate that
PCR and ACR are equivalent to 24 h urine protein in order to recom-
mend them as replacements. This study, involving an endothelin re-
ceptor antagonist, suggests that PCR and ACR are comparable to
24 h urine protein in terms of both agreement and repeatability.
However, a randomised control trial comparing all three assays in a
larger and more diverse population is necessary before 24 h urine
protein can be appropriately substituted in the clinical trial context.Addendum
Sitaxentan has been voluntarily withdrawn by Pﬁzer Ltd due to
unacceptable side effects. However, the ﬁndings in this manuscript
remain true for selective endothelin A receptor antagonism.Sources of funding
This study was funded by Encysive Pharmaceuticals, Inc. In June
2008, Encysive was acquired by Pﬁzer, Inc. N.D. was supported by the
British Heart Foundation and National Health Service endowments.Conﬂict of interest statement
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